Form 4: CVRx CFO Boosts Equity Holdings, Sells for Tax

CVRx Chief Financial Officer Jared Oasheim acquired 61,000 restricted stock units and 91,000 stock options, while selling 1,744 shares to cover tax obligations.

Summary

• Chief Financial Officer Jared Oasheim acquired 61,000 Restricted Stock Units (RSUs) of CVRx, Inc. common stock on February 27, 2026, at a price of $0.
• These RSUs are scheduled to vest as to 25% of the shares on each annual anniversary of the grant date.
• Oasheim also acquired 91,000 stock options to buy CVRx common stock on February 27, 2026, with an exercise price of $8.16.
• These stock options will vest as to 25% of the shares on February 27, 2027, and as to 1/48th of the shares each month thereafter, with an expiration date of February 26, 2036.
• Oasheim sold 1,744 shares of CVRx common stock on March 2, 2026, at a weighted average price of $7.9022 per share.
• This sale was a mandated 'sell-to-cover' transaction to satisfy tax withholding obligations related to an issuer's award agreement.
• Following these transactions, Oasheim beneficially owns 96,703 shares of common stock, 61,000 Restricted Stock Units, and 91,000 stock options.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as the CFO is increasing his overall equity exposure through significant RSU and option grants, despite a small, tax-mandated sale.

Positives

• Chief Financial Officer Jared Oasheim significantly increased his overall equity exposure in CVRx, Inc. through the acquisition of 61,000 Restricted Stock Units and 91,000 stock options, aligning his long-term interests with shareholders.

Negatives

• Chief Financial Officer Jared Oasheim sold 1,744 shares of common stock, although this was a routine 'sell-to-cover' transaction for tax withholding purposes rather than a discretionary sale.

Future Outlook

The acquired Restricted Stock Units will vest 25% annually from the grant date, and the stock options will vest 25% on February 27, 2027, with 1/48th vesting monthly thereafter, aligning the CFO's long-term incentives with company performance.

Management Comments

• The sale of 1,744 shares was mandated by the issuer's award agreement to satisfy tax withholding obligations by a sell-to-cover transaction.

Industry Context

StockSavvy.ai notes that insider equity grants are a common practice to incentivize executives and align their interests with long-term shareholder value, particularly in growth-oriented medical device companies like CVRx. The 'sell-to-cover' transaction is a standard mechanism for managing tax liabilities associated with equity compensation.

Stakeholder Impact

• Shareholders: The increase in the CFO's equity holdings through grants aligns his financial interests with long-term shareholder value creation.
• Employees: Standard equity compensation practices can signal a stable and competitive compensation structure within the company.

Next Steps

• Continued vesting of 61,000 Restricted Stock Units annually from February 27, 2026.
• Continued vesting of 91,000 stock options, with 25% vesting on February 27, 2027, and 1/48th monthly thereafter until February 26, 2036.

Key Dates

Recommendation

The filing details routine insider transactions related to compensation and tax obligations. While the CFO is increasing his long-term equity exposure, the transactions themselves do not provide new fundamental information about the company's operational performance or strategic direction that would warrant a change in investment recommendation. It reinforces alignment but doesn't alter the investment thesis.

Keywords

CVRx, CVRX, insider transaction, Form 4, beneficial ownership, stock options, restricted stock units, CFO, equity compensation